Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC lessened its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 28.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 182,668 shares of the company's stock after selling 74,212 shares during the quarter. Nuveen Asset Management LLC owned 0.23% of Kura Oncology worth $1,591,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Virtus ETF Advisers LLC raised its stake in Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after buying an additional 3,061 shares during the period. Harbor Advisors LLC bought a new stake in Kura Oncology during the fourth quarter worth $87,000. E Fund Management Co. Ltd. bought a new stake in Kura Oncology during the fourth quarter worth $90,000. Corton Capital Inc. bought a new position in shares of Kura Oncology in the 4th quarter valued at $99,000. Finally, Optimize Financial Inc bought a new position in shares of Kura Oncology in the 4th quarter valued at $100,000.

Kura Oncology Price Performance

Shares of NASDAQ KURA traded up $0.16 during trading on Friday, hitting $6.73. The company had a trading volume of 765,456 shares, compared to its average volume of 1,216,493. The firm has a market capitalization of $582.65 million, a price-to-earnings ratio of -2.85 and a beta of 0.40. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The stock has a fifty day simple moving average of $6.07 and a two-hundred day simple moving average of $7.69. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. On average, research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on KURA shares. UBS Group reduced their target price on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Wall Street Zen downgraded Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. JMP Securities reiterated a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a research report on Wednesday. Wedbush reissued an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a research note on Tuesday, April 8th. Finally, Mizuho reduced their price objective on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, May 19th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $24.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.